This paper is only available as a PDF. To read, Please Download here.
In this double-masked, double-dummy, randomized, single crossover study, we compared single doses of a fast-dissolving wafer formulation of famotidine with a conventional tablet formulation of ranitidine in patients with gastroesophageal reflux disease (GERD). Patient preference, time until symptomatic relief, and predictive characteristics of early responders were assessed. Eligible patients had a clinical diagnosis of GERD and symptoms of GERD of sufficient severity to require relief. The study treatment was one dose of famotidine (20-mg wafer) and one dose of ranitidine (150-mg tablet), which were given in a randomized order and taken as needed. The patients were instructed to measure the symptomatic effects on a seven-point categorical scale (1 = worse to 7 = free of symptoms) at 15, 30, 45, 60, 120, and 180 minutes. After the clinical phase of the trial, the patients indicated their global assessment of efficacy and their preference for the wafer or the tablet. Of the 829 patients who completed the study, significantly more preferred the wafer to the tablet. While there was no significant difference in the global assessment of efficacy, the famotidine wafer provided significantly better relief than the ranitidine tablet during the first hour after dosing. However, at 120 and 180 minutes, the degree of relief was similar for the two drugs. The time until a clinically significant effect was also similar for the two drugs, and approximately one half of the patients experienced such improvement within 3 hours. Multivariate analyses disclosed no predictive characteristics of early symptomatic effect
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The intensity and variability of symptoms in dyspepsia.Scand J Prim Health Care. 1992; 11: 50-55
- Cimetidine on-demand in dyspepsia: Experiences with randomized controlled single subject trials.Scand J Gastroenterol. 1992; 27: 189-195
- Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease.Scand J Gastroenterol. 1987; 22: 714-718
- Oesophagitis. Signs of reflux and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease.Scand J Gastroenterol. 1986; 21: 837-847
- Heartburn—the acid test.Gut. 1989; 30: 1523-1525
- Functional dyspepsia: A classification with guidelines for diagnosis and management.Gastroenterol Int. 1991; 4: 145-160
- Long-term strategy for the treatment of gastro-oesophageal reflux disease.Gastroenterol Int. 1991; 4: 21-32
- Novel oral medication delivery system for famotidine.J Clin Pharmacol. 1995; 35: 362-367
- Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer disease and other allied disease.Drugs. 1982; 24: 267-303
© 1997 Published by Elsevier Inc.